Cargando…
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
Identifying genetic biomarkers of synthetic lethal drug sensitivity effects provides one approach to the development of targeted cancer therapies. Mutations in ARID1A represent one of the most common molecular alterations in human cancer, but therapeutic approaches that target these defects are not...
Autores principales: | Williamson, Chris T., Miller, Rowan, Pemberton, Helen N., Jones, Samuel E., Campbell, James, Konde, Asha, Badham, Nicholas, Rafiq, Rumana, Brough, Rachel, Gulati, Aditi, Ryan, Colm J., Francis, Jeff, Vermulen, Peter B., Reynolds, Andrew R., Reaper, Philip M., Pollard, John R., Ashworth, Alan, Lord, Christopher J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5159945/ https://www.ncbi.nlm.nih.gov/pubmed/27958275 http://dx.doi.org/10.1038/ncomms13837 |
Ejemplares similares
-
CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2016) -
Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2016) -
Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2017) -
Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2018) -
Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities
por: Sanjiv, Kumar, et al.
Publicado: (2015)